Banner

About CavoGene

Cosmetic Water Bubble DNA and mRNA Helix Cell Medical Presentation Background with Copy Space

Image grid

Text

<p>CavoGene LifeSciences is committed to individuals worldwide who are impacted by various neurodegenerative diseases. We are dedicated to the discovery, development and commercialization of novel gene therapies that attenuate memory loss and increase synaptic neuroplasticity, such as Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, and Traumatic Brain Injury.</p>
<p>Our team is currently testing a novel gene therapy platform initially targeting treatment of ALS, also known as Lou Gehrig's disease. Importantly, CavoGene’s gene therapy is distinct from all other gene therapies that are currently being developed since SynCav1 targets all forms of ALS, both familial (genetic, causes less than 10% of ALS) and sporadic (90%+ of all ALS patients). Our therapy is both neuroprotective and promotes functional neuroplasticity to restore neuronal function in order to improve the quality of life for individuals afflicted with ALS.</p>

List

SynCav1 Demonstrates In Vitro Efficacy in Human Neurons

<ul>
<li>Neuron specific gene therapy that delivers Caveolin-1 to promote neuronal plasticity &amp; synaptic communication to facilitate neuronal repair</li>
</ul>

<ul>
<li>Proof of Concept: SynCav1 treatment demonstrated significant increases in dendritic and axonal growth in human neurons derived from induced pluripotent stem cells (iPSCs)</li>
</ul>